Spinal Muscular Atrophy - Gene Therapy Itvisma
Customize your policy alerts
Sign up for Cigna Policy IP0790 alerts
Get alerted when Policy IP0790 changes without checking for updates manually.
Monitor payer policy activity
Defines Cigna coverage, prior authorization, clinical and laboratory criteria, dosing, and exclusions for Itvisma for treatment of spinal muscular atrophy in pediatric and adolescent patients; affects providers who prescribe/administer Itvisma and those submitting claims.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial (FDA-indication) coverage criteria
Covered when ALL of the following are met
All items marked documentation required must be supplied
FDA-Approved Indication / Initial Therapy
Covered when ALL of the following are met:
Includes infectious disease exclusions and therapy-discontinuation confirmations
Use of Itvisma for any indication not explicitly meeting the policy’s coverage conditions is considered not medically necessary. The policy lists specific examples of non‑covered situations to guide clinical decision making and claims adjudication.
Itvisma is considered not medically necessary for patients who meet any of the following specific conditions: (1) Complete paralysis of all limbs; (2) Permanent ventilator dependence; or (3) Prior receipt of gene therapy. The policy notes that Itvisma has not been studied in previously gene‑treated patients and that evidence is needed to determine benefit in the other listed populations.
The policy explicitly states that administration of Itvisma is not medically necessary for patients with complete paralysis of all limbs, for those with permanent ventilator dependence, and for patients who have had a prior receipt of gene therapy. These conditions are called out because available data do not establish benefit of Itvisma in these populations.
Any use of Itvisma that does not meet the policy’s listed coverage criteria or that falls within the conditions enumerated above is considered not medically necessary and may be denied. The examples provided in the policy are not exhaustive; the list may be updated as new evidence emerges.
Initial Therapy Criteria
Initial therapy and dosing
Initial dosing and approval
Approval duration granted for 90 days to allow preparation and administration.
Initial Therapy
Initial coverage is for a single, per-lifetime dose when all criteria are met.
Approves one lifetime dose if all listed conditions A–N are satisfied
Coding and Test Criteria
| C9309 | Injection, onasemnogene abeparvovec-brve, per treatment (Code effective until 6/30/2026) |
| J3405 | Injection, onasemnogene abeparvovec-brve, per treatment |
Provider Actions / Billing
Require prior authorization for one-time dose
Prior Authorization is required for benefit coverage of Itvisma. All approvals are provided for one time (per lifetime) as a single dose. The approval duration is 90 days to allow for preparation and administration. The medication must be prescribed by a physician who has consulted with or who specializes in the condition.
- Approval is one-time (per lifetime) single dose.
- Authorization duration: 90 days to prepare and administer.
Authorization and billing must use covered HCPCS codes
Prior authorization is required for the one-time intrathecal Itvisma dose (1.2 x 10^14 vector genomes). Claims must be billed with the appropriate covered HCPCS code (C9309 or J3405) when criteria are met.
- Dose: single intrathecal injection of 1.2 x 10^14 vector genomes.
- Covered HCPCS codes: C9309 or J3405.
Confirm discontinuation of Spinraza or Evrysdi
If the patient is currently receiving Spinraza (nusinersen) or Evrysdi (risdiplam), the prescribing physician must confirm that those therapies will be discontinued prior to approval and administration of Itvisma.
- Confirmation applies to patients currently receiving or who have received prior Spinraza.
- Confirmation applies to patients currently receiving or who have received prior Evrysdi.
Therapy sequencing: discontinuation confirmation required
While not defined as step therapy, the policy requires physician confirmation that prior or current Spinraza or Evrysdi therapy will be discontinued before Itvisma administration and approval.
- Not a step-therapy sequence; requirement is discontinuation confirmation by prescribing physician.
Provide required documentation with identifying information
Documentation is required and may include chart notes, laboratory results, medical test results, claims records, prescription receipts, and other patient‑specific information. All documentation must include patient identifying information.
- Documentation must support genetic testing confirming SMN1 pathogenic variants and required lab results (AAV9 titer, liver, renal, CBC).
- All documentation must include patient-specific identifying information.
Prescriber must confirm discontinuation of prior SMA therapies
The prescribing physician must specifically confirm discontinuation of prior Spinraza (nusinersen) or Evrysdi (risdiplam) for patients who are currently receiving or have previously received those therapies as a condition of approval.
- Confirmation required for prior or current Spinraza therapy.
- Confirmation required for prior or current Evrysdi therapy.
Claims without covered codes will be denied
Claims submitted for services that are not accompanied by covered code(s) under this policy will be denied as not covered; providers must use the most appropriate covered codes when billing.
- Use covered HCPCS codes C9309 or J3405 for Itvisma when criteria are met.
- Deleted or non‑effective codes at time of service may not be eligible for reimbursement.
Non-coverage when excluded conditions apply
Use of Itvisma for conditions listed under 'Conditions Not Covered' (e.g., complete paralysis of all limbs, permanent ventilator dependence, or prior receipt of gene therapy) may be considered not medically necessary and could trigger denial.
- Do not submit claims for patients with complete paralysis of all limbs or permanent ventilator dependence.
- Prior receipt of gene therapy is an exclusion and may result in denial.
Step Therapy / Sequencing
| Requirement | Provider action / documentation |
|---|---|
| Prior or current treatment with Spinraza (nusinersen) | Prescribing physician must confirm Spinraza will be discontinued prior to approval; include documentation in the prior authorization request (chart note or medication history). |
| Prior or current treatment with Evrysdi (risdiplam) | Prescribing physician must confirm Evrysdi will be discontinued prior to approval; include documentation in the prior authorization request (chart note or medication history). |
Quantity Limits
Site of Care
Prescriber consultation and specialized administration required
Because specialized skills are required for evaluation and administration, Itvisma must be prescribed by a physician who has consulted with or specializes in SMA/neuromuscular disorders and administration requires specialized training.
- Prescribing physician must have consulted with or specialize in SMA/neuromuscular disorders
- Administration requires specialized training (site of care consideration)
Definitions
Background
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by pathogenic variants in SMN1 leading to reduced SMN protein and motor neuron loss; disease severity is modulated by SMN2 copy number. Itvisma (onasemnogene abeparvovec intrathecal) is an adeno‑associated virus vector–based gene therapy developed for treatment of SMA in pediatric and adolescent patients and is addressed in this policy for the FDA‑approved age range. The policy’s coverage and exclusion statements reflect current evidence limitations, including lack of study of Itvisma in patients with prior gene therapy, complete limb paralysis, or permanent ventilator dependence.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.